'Unprecedented' Responses to Neoadjuvant Tx in dMMR Colon Cancer
An 'innovative' study of short-course nivolumab plus ipilimumab prior to resection of MMR-deficient colon cancer has achieved 'unprecedented' pathologic responses, with no recurrences.
Medscape Medical News
source https://www.medscape.com/viewarticle/980548?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/980548?src=rss
Comments
Post a Comment